source
- STAT+: Pharma’s drug spending deflectionJob lock, surging prescription drug costs, No Surprises Act update, and more from STAT's Health Care Inc.
- Capricor's DMD therapy lacks efficacy, FDA says ahead of adcommThe FDA is again questioning the efficacy of Capricor's cell therapy for Duchenne muscular dystrophy, this time ahead of an advisory committee meeting on Wednesday. The agency's review team said it…